# A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

> **NCT01942382** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 76 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone palmitate

## Key facts

- **NCT ID:** NCT01942382
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2013-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01942382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01942382, "A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01942382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*